Literature DB >> 10696090

Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.

F L Ricciardolo1, M Trevisani, P Geppetti, J A Nadel, S Amadesi, C Bertrand.   

Abstract

The tachykinin, neurokinin A (NKA), contracts guinea-pig airways both in vitro and in vivo, preferentially activating smooth muscle NK(2) receptors, although smooth muscle NK(1) receptors may also contribute. In vitro evidence suggests that NKA activates epithelial NK(1) receptors, inducing the release of nitric oxide (NO) and subsequent smooth muscle relaxation. A number of selective NK(1) receptor agonists have been reported to activate both smooth muscle and epithelial NK(1) receptors, however septide appears only to activate smooth muscle NK(1) receptors. The aim of the present study was to investigate whether NKA-induced bronchoconstriction in guinea-pigs in vivo may be limited by NO release via NK(1) receptor activation, and whether selective NK(1) receptor agonists may activate this mechanism differently. Aerosolized NKA caused an increase in total pulmonary resistance (RL) that was markedly reduced by the NK(2) receptor antagonist, SR 48968, and abolished by the combination of SR 48968 and the NK(1) receptor antagonist, CP-99, 994. The increase in RL evoked by NKA was potentiated by pretreatment with the NO synthase (NOs) inhibitor, L-NAME, but not by the inactive enantiomer D-NAME. Potentiation by L-NAME of NKA-induced increase in RL was reversed by L-Arginine, but not by D-Arginine. Pretreatment with L-NAME did not affect the increase in RL induced by the selective NK(2) receptor agonist, [beta-Ala(8)]NKA(4-10), and by the selective NK(1) receptor agonist, septide, whereas it markedly potentiated the increase in RL caused by a different NK(1) selective agonist, [Sar(9),Met(O(2))(11)]SP. Dose-response curves showed that septide was a more potent bronchoconstrictor than [Sar(9),Met(O(2))(11)]SP to cause bronchoconstriction. Pretreatment with the NK(1) receptor antagonist, CP-96,994, abolished the ability of L-NAME to increase bronchoconstriction to aerosolized NKA. Bronchoconstriction to aerosolized NKA was increased by L-NAME, after pretreatment with the NK(3) receptor antagonist, SR 142801. The present study shows that in vivo bronchoconstriction in response to the aerosolized naturally occurring tachykinin, NKA, is limited by its own ability to release relaxant NO via NK(1) receptor activation. This receptor is apparently insensitive to septide, thus justifying, at least in part, the high potency of septide to cause bronchoconstriction in guinea-pigs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696090      PMCID: PMC1571918          DOI: 10.1038/sj.bjp.0703135

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.

Authors:  X Emonds-Alt; P Vilain; P Goulaouic; V Proietto; D Van Broeck; C Advenier; E Naline; G Neliat; G Le Fur; J C Brelière
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Tachykinin receptors and noncholinergic bronchoconstriction in the guinea-pig isolated bronchi.

Authors:  C A Maggi; R Patacchini; P Rovero; P Santicioli
Journal:  Am Rev Respir Dis       Date:  1991-08

Review 3.  Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons.

Authors:  P Holzer
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

4.  Airway neutral endopeptidase-like enzyme modulates tachykinin-induced bronchoconstriction in vivo.

Authors:  D J Dusser; E Umeno; P D Graf; T Djokic; D B Borson; J A Nadel
Journal:  J Appl Physiol (1985)       Date:  1988-12

5.  SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor.

Authors:  X Emonds-Alt; D Bichon; J P Ducoux; M Heaulme; B Miloux; M Poncelet; V Proietto; D Van Broeck; P Vilain; G Neliat
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

6.  Bronchodilatation by tachykinins and capsaicin in the mouse main bronchus.

Authors:  S Manzini
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

7.  Role of kinins in anaphylactic-induced bronchoconstriction mediated by tachykinins in guinea-pigs.

Authors:  F L Ricciardolo; J A Nadel; P D Graf; C Bertrand; S Yoshihara; P Geppetti
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

8.  In vivo evidence for the activation of a septide-sensitive tachykinin receptor in guinea pig bronchoconstriction.

Authors:  P Boni; C A Maggi; S Evangelista
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

9.  Evidence for reduction of bradykinin-induced bronchoconstriction in guinea-pigs by release of nitric oxide.

Authors:  F L Ricciardolo; J A Nadel; S Yoshihara; P Geppetti; S Yoishihara
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

10.  Evidence that antidromically stimulated vagal afferents activate inhibitory neurones innervating guinea-pig trachealis.

Authors:  B J Canning; B J Undem
Journal:  J Physiol       Date:  1994-11-01       Impact factor: 5.182

View more
  3 in total

1.  Role of nitric oxide and superoxide in allergen-induced airway hyperreactivity after the late asthmatic reaction in guinea-pigs.

Authors:  J de Boer; H Meurs; L Flendrig; M Koopal; J Zaagsma
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 2.  Multiple roles of nitric oxide in the airways.

Authors:  F L M Ricciardolo
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 3.  Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.

Authors:  Christopher J Czura; Marom Bikson; Leigh Charvet; Jiande D Z Chen; Manfred Franke; Marat Fudim; Eric Grigsby; Sam Hamner; Jared M Huston; Navid Khodaparast; Elliot Krames; Bruce J Simon; Peter Staats; Kristl Vonck
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.